LifeVantage Q3 Revenue Plunges 25%, Profits Halved Amid 'Softer Than Anticipated' Results
summarizeSummary
LifeVantage reported significantly weaker-than-anticipated third-quarter fiscal 2026 financial results, with revenue plummeting 25.2% year-over-year to $43.7 million and net income per diluted share more than halving to $0.11 from $0.26. Adjusted EBITDA also saw a steep 50% decline to $3.2 million. These results continue a negative trend, following the steep revenue and net income declines reported in Q2 2026. The interim CEO acknowledged the "softer than anticipated" performance, attributing it partly to lower sales of the MindBody GLP-1 System® and an allowance for inventory obsolescence. For a company of LifeVantage's size, these substantial declines across key financial metrics are highly material and indicate ongoing operational challenges, likely prompting a negative market reaction. Investors will be watching for signs of stabilization or further deterioration in sales and profitability.
At the time of this announcement, LFVN was trading at $5.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.8M. The 52-week trading range was $3.90 to $15.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.